• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, June 14, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Cancer genomics: Addressing treatment resistance in childhood acute lymphoblastic leukemia

Bioengineer by Bioengineer
December 20, 2016
in Science News
Reading Time: 3 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In the third week of PLOS Medicine's ongoing special issue on cancer genomics, principal investigator Jules Meijerink of the Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands and colleagues seek to identify mechanisms underlying treatment resistance in children with T-cell acute lymphoblastic leukemia (T-ALL) by combining genomic DNA sequencing and chromosomal copy-number analyses, and suggest a new approach to therapy.

Treatment of childhood leukemia has improved markedly in recent decades, with long-term cure achieved in most patients who have access to modern, highly intensive treatment regimens. However, some patients develop resistance to the steroid drugs which are a key part of combination chemotherapy treatments, which results in poor clinical outcomes. As described in their Research Article, Meijerink and colleagues studied genetic changes in leukemic cells from pediatric T-ALL patients before treatment. The researchers found specific gene mutations affecting signaling inside cells, involving the interleukin 7 receptor and downstream molecules, that were associated with steroid resistance and adverse clinical outcome. Drugs designed to target individual signaling proteins were able to restore steroid sensitivity to primary leukemic cells from patients.

Discussing the research in an accompanying Perspective article, Steven Goossens and Pieter Van Vlierberghe conclude that "inhibition of MEK-ERK or PI3K/AKT/mTOR signaling could enhance steroid sensitivity in T-ALL and potentially improve patient outcomes, a notion that warrants investigation in future prospective clinical trials."

###

Research Article

Funding: YL was funded by Stichting Kinderen Kankervrij (https://www.kika.nl; KiKa-2010-082). KC-B and WKS were funded by Stichting Kinderen Kankervrij (https://www.kika.nl; KiKa-2008-029, KiKa-2013-116). EMV was funded by KWF Kanker Bestrijding (https://www.kwf.nl; EMCR-KWF-2010-4691). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: RCB and GJRZ are founders and shareholders of Netherlands Translational Research Center B.V. The other authors have declared that no competing interests exist.

Citation: Li Y, Buijs-Gladdines JGCAM, Canté-Barrett K, Stubbs AP, Vroegindeweij EM, Smits WK, et al. (2016) IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med 13(12): e1002200. doi:10.1371/journal.pmed.1002200

Author Affiliations:
Department of Pediatric Oncology/Hematology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Department of Bioinformatics, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
Research Institute Children's Cancer Center Hamburg, Hamburg, Germany
Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Co-operative Study Group for Childhood Acute Lymphoblastic Leukemia, Hamburg, Germany
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
Netherlands Translational Research Center, Oss, The Netherlands

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002200

Perspective Article

Funding: The authors received no funding for this work.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Goossens S, Van Vlierberghe P (2016) Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia. PLoS Med 13(12): e1002208. doi:10.1371/journal.pmed.1002208

Author Affiliations:
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
Department for Biomedical Molecular Biology, Ghent University, Ghent, Belgium
Cancer Research Institute Ghent (CRIG), Ghent, Belgium

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002208

Media Contact

Jules Meijerink
[email protected]

Home

############

Story Source: Materials provided by Scienmag

Share13Tweet7Share2ShareShareShare1

Related Posts

Device

Rewrite Two frontiers: Illinois experts combine forces to develop novel nanopore sensing platform this news headline for the science magazine post

June 13, 2025
Distribution network architecture

Rewrite Review of active distribution network reconfiguration: Past progress and future directions this news headline for the science magazine post

June 13, 2025

Rewrite University of Cincinnati structural biology research published in prestigious PNAS this news headline for the science magazine post

June 13, 2025

Rewrite FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research this news headline for the science magazine post

June 13, 2025
Please login to join discussion

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    158 shares
    Share 63 Tweet 40
  • New Study Uncovers Unexpected Side Effects of High-Dose Radiation Therapy

    74 shares
    Share 30 Tweet 19
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    68 shares
    Share 27 Tweet 17
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Rewrite Two frontiers: Illinois experts combine forces to develop novel nanopore sensing platform this news headline for the science magazine post

Rewrite Review of active distribution network reconfiguration: Past progress and future directions this news headline for the science magazine post

Rewrite University of Cincinnati structural biology research published in prestigious PNAS this news headline for the science magazine post

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.